EC Number   |
Application |
Reference |
|---|
   2.7.8.27 | analysis |
development of a high-throughput screening assay |
761026 |
| 2.7.8.27 | drug development |
enzyme SMS1 is a drug target for the treatment of atherosclerosis |
737844 |
| 2.7.8.27 | drug development |
SMS is a target for drug design |
691074 |
| 2.7.8.27 | medicine |
adenovirus-mediated SMS1 overexpression increases lipoprotein atherogenic potential. Such an effect may contribute to the increased plasma sphingomyelin levels observed in animal models of atherosclerosis and in human patients with coronary artery disease |
669762 |
| 2.7.8.27 | medicine |
adenovirus-mediated SMS2 overexpression increases lipoprotein atherogenic potential. Such an effect may contribute to the increased plasma sphingomyelin levels observed in animal models of atherosclerosis and in human patients with coronary artery disease |
669762 |
| 2.7.8.27 | medicine |
regulation of liver SMS2 may be used as treatment for atherosclerosis |
707306 |
| 2.7.8.27 | medicine |
SMS inhibitors might be useful for the treatment of atherosclerosis or coronary artery disease |
738955 |
| 2.7.8.27 | medicine |
SMS2 is a potential therapeutic target for treatment of atherosclerosis |
708149 |
| 2.7.8.27 | medicine |
sphingomyelin synthase is a potential target for tricyclodecan-9-yl-xanthogenate (D609) and inhibition of sphingomyelin synthase may contribute to D609-induced cell death via modulation of the cellular levels of ceramide and diacylglycerol |
668494 |
| 2.7.8.27 | pharmacology |
sphingomyelin synthase 2 (SMS2) is a potential therapeutic target for obesity and insulin resistance |
-, 737776 |
